In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 11, 2018, Pages

  Brown Elliott, Barbara A ^a   Rubio, Aileen ^b   Wallace, Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Drug Product Development   (United States)

Author keywords

Benzimidazole; Nontuberculous mycobacteria; SPR719

Indexed keywords

AMIKACIN; BENZIMIDAZOLE; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; PRODRUG; RIFABUTIN; RIFAMPICIN; SPR 719; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG POTENCY; IN VITRO STUDY; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM MASSILIENSE; MYCOBACTERIUM MUCOGENICUM; MYCOBACTERIUM SIMIAE; NONHUMAN; PRIORITY JOURNAL; ATYPICAL MYCOBACTERIOSIS; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 85055609877     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01503-18     Document Type: Article

References (10)

1. Brown-Elliott BA, Nash KA, Wallace RJ, Jr. 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 25:545–582. https://doi.org/10.1128/CMR.05030-11.
2. Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, Ngwane AH, Wiid IJ, van Helden PD, Betoudji F, Nuermberger EL, Thomson JA. 2015. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother 59:1455–1465. https://doi.org/10.1128/AAC.04347-14.
3. Brown-Elliott BA, Ashcraft M, Bush G, McKinney A, Ritter K, Shipp K, Mooney J, Wallace RJ, Jr, Rubio A. 2018. In vitro characterization of a novel gyrase inhibitor (SPR719) against nontuberculous mycobacteria, ASM Microbe, Atlanta, GA.
4. Clinical and Laboratory Standards Institute. 2008. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. CLSI document MM18-A. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Adékambi T, Colson P, Drancourt M. 2003. rpo B-based identification of nonpigmented and late pigmented rapidly growing mycobacteria. J Clin Microbiol 41:5699–5708. https://doi.org/10.1128/JCM.41.12.5699-5708.2003.
6. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved Standard, 2nd edition. Document no. M24–A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Shoen C, Pucci MJ, DeStefano M, Cynamon M. 2017. Efficacy of SPR 720 and SPR 750 gyrase inhibitors in a mouse Mycobacterium tuberculosis infection model, ASM Microbe 2017, New Orleans, LA.
8. Rubio A, Verma D, Ordway D, Pucci MJ, Parr TR, Jr. 2017. Activity of a novel gyrase inhibitor in vitro and in an acute SCID mouse model of infection caused by Mycobacterium abscessus. ASM Microbe 2017, New Orleans, LA.
9. Rubio A, Stapleton M, Verman D, Ordway D. 2018. Potent activity of a novel gyrase inhibitor (SPR719/720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection, ASM Microbe 2018, Atlanta, GA.
10. Bermudez LE, Palmer A, Rubio A. 2018. Treatment of Mycobacterium avium subspecies hominissuis (MAH) infection with a novel gyrase inhibitor (SPR719/SPR720) was associated with a significant decrease in bacterial load as assessed in macrophages, biofilm and in mice, ASM Microbe 2018, Atlanta, GA.